ARTISAN ACQUISITION CORP.

(ARTA)
  Report
Delayed Nasdaq  -  05/13 03:59:29 pm EDT
10.37 USD   +1.57%
05/10ARTISAN ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/02Ladenburg Thalmann Initiates Artisan Acquisition at Buy with $15 Price Target
MT
03/31ARTISAN ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Hong Kong COVID testing firm Prenetics to go public via $1.7 bln SPAC deal

09/15/2021 | 10:23pm EDT

* Prenetics to get up to $459 mln in cash proceeds from deal

* Prenetics revenue seen up three-fold to $205 mln in 2021 vs 2020

* COVID business to account for 20% of 2023 revenue -Prenetics CEO

HONG KONG, Sept 16 (Reuters) - Hong Kong-based COVID-19 testing company Prenetics will go public via a merger agreement with Artisan Acquisition, in a deal that will value the pairing at $1.7 billion.

The companies announced the deal on Thursday with the transaction valuing Prenetics at an enterprise value of $1.25 billion with a combined equity value of around $1.7 billion.

The biotech will be the "first unicorn from Hong Kong to be publicly listed in any market," the companies said in their statement, riding a boom in COVID-19 testing globally.

Artisan, a special purpose acquisition company (SPAC), is backed by Hong Kong property tycoon Adrian Cheng, chief executive of New World Development.

The deal highlights strong investor interest in Asian biotech startups with technology that has global applications amid the pandemic. Chinese biotech companies have been rushing to raise funds in the stock market as well, encouraged by the government's push to introduce more innovative treatments. https://www.reuters.com/world/china/chinas-biotech-sector-comes-age-with-big-licensing-deals-global-ambitions-2021-09-15

Asia was part of a global surge in SPAC-related deals at the start of 2021, but transactions have slowed with investors more prudent about which de-SPAC deals they want to support.

De-SPAC transactions - when SPACs merge with target firms - involving Asian companies have totalled $55 billion this year, about a tenth of the global amount, Refinitiv data shows.

The combined market value of Chinese biotechs listed in Hong Kong, on Shanghai's STAR board and on the Nasdaq was some $180 billion as of May, which compares to just $1 billion in 2016, according to consulting firm McKinsey.

Prenetics will receive up to $459 million in cash proceeds, including $120 million raised from investors including Aspex, PAG, Xen Capital and conglomerate Lippo Group.

The combined company will be traded on the Nasdaq. The deal is expected to close in the fourth quarter of 2021 or the first quarter of 2022, the companies said.

M&A AMBITIONS

Prenetics, founded in 2014, specializes in genomic and diagnostic testing and is the number one such company in Hong Kong and Britain, according to the statement.

Its clients include the Hong Kong government, Hong Kong International Airport, London Heathrow Airport, the English Premier League and Virgin Atlantic, the statement said.

Prenetics plans to expand its scope of products from its current concentration of COVID-19 testing to influenza and sexually transmitted diseases in the next few years, with COVID-related business to make up 20% of its revenue in 2023, its co-founder and CEO Danny Yeung told Reuters.

Prenetics is also looking to acquire companies that offer technology in the rapid diagnostic testing, genomics and laboratory areas over the next five years with a priority in the United States, Yeung said.

"We are entirely focused on international (market expansion). We have no aspirations to go into the mainland Chinese market," he said.

"We have limited resources and we want to be able to go into the markets where we can win."

As part of the SPAC deal, Prenetics' existing equity holders will roll their equity into the combined company.

Prenetics' expects its revenue to jump more than three-fold to $205 million in 2021 from $65 million in 2020, and to more than $600 million in 2025.

UBS and Citigroup are financial advisers to Artisan and Prenetics, respectively. (Reporting by Kanishka Singh in Bengaluru and Kane Wu and Farah Master in Hong Kong; Editing by Stephen Coates and Himani Sarkar)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ARTISAN ACQUISITION CORP. 1.57% 10.37 Delayed Quote.4.64%
CITIGROUP INC. 2.32% 47.64 Delayed Quote.-21.11%
NASDAQ COMP. 3.82% 11805 Real-time Quote.-24.54%
NEW WORLD DEVELOPMENT COMPANY LIMITED 0.52% 28.8 Delayed Quote.-7.13%
TYCOON GROUP HOLDINGS LIMITED 0.00% 1.26 Delayed Quote.-5.97%
UBS GROUP AG 1.19% 17.435 Delayed Quote.4.93%
All news about ARTISAN ACQUISITION CORP.
05/10ARTISAN ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Eve..
AQ
05/02Ladenburg Thalmann Initiates Artisan Acquisition at Buy with $15 Price Target
MT
03/31ARTISAN ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disc..
AQ
03/04ARTISAN ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition ..
AQ
03/04Artisan Acquisition Corp. Reports Earnings Results for the Eleven Months Ended December..
CI
2021ARTISAN ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
2021Certain Class B Ordinary Shares of Artisan Acquisition Corp. are subject to a Lock-Up A..
CI
2021ARTISAN ACQUISITION : Blank-Check Firm Artisan Acquisition to Merge With Prenetics Group
MT
2021Hong Kong COVID testing firm Prenetics to go public via $1.7 bln SPAC deal
RE
2021ARTISAN ACQUISITION : Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Bec..
PU
More news
Analyst Recommendations on ARTISAN ACQUISITION CORP.
More recommendations
Financials (USD)
Sales 2022 341 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 455 M 455 M -
Capi. / Sales 2022 1,33x
Capi. / Sales 2023 1,15x
Nbr of Employees -
Free-Float 68,3%
Chart ARTISAN ACQUISITION CORP.
Duration : Period :
Artisan Acquisition Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 10,37 $
Average target price 15,00 $
Spread / Average Target 44,6%
Managers and Directors
Yin Pan Cheng Chief Executive Officer & Director
William Robert Keller Independent Director
Mitchell Alan Garber Independent Director
Fan Yu Independent Director
Sean O’Neill Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ARTISAN ACQUISITION CORP.4.64%455
INVESTOR AB (PUBL)-20.03%55 456
CK HUTCHISON HOLDINGS LIMITED8.55%26 670
GROUPE BRUXELLES LAMBERT SA-13.67%12 856
HAL TRUST-8.64%12 021
AB INDUSTRIVÄRDEN (PUBL)-13.80%10 624